<?xml version="1.0" encoding="utf-8" ?>
<INTERACTIONS>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>286-TYPE-5-PHOSPHODIESTERASE-INHIBITORS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="TYPE 5 PHOSPHODIESTERASE INHIBITORS" code="G04BE" /></DRUG1>
<DRUG2>
<CLASS name="ALPHA BLOCKERS FOR UROLOGICAL USE" code="G04CA-001" /></DRUG2>
<DESCRIPTION>Risk of orthostatic hypotension, especially with older patients

</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>-with the doxazosin</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>286-TYPE-5-PHOSPHODIESTERASE-INHIBITORS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="TYPE 5 PHOSPHODIESTERASE INHIBITORS" code="G04BE" /></DRUG1>
<DRUG2>
<CLASS name="ANTIHYPERTENSIVE ALPHA BLOCKERS" code="C02CA0-001" /></DRUG2>
<DESCRIPTION>Risk of orthostatic hypotension, especially with older patients</DESCRIPTION>
<SEVERITY>Not recommended </SEVERITY>
<COMMENT>-with the doxazosine</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>286-TYPE-5-PHOSPHODIESTERASE-INHIBITORS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="TYPE 5 PHOSPHODIESTERASE INHIBITORS" code="G04BE" /></DRUG1>
<DRUG2>
<CLASS name="NITRATE DERIVATIVES AND RELATED" code="C01D-001" /></DRUG2>
<DESCRIPTION>Risk of significant hypotension (synergic effect) capable of aggravating the state of myocardial ischemia and provoking an acute coronary accident</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>286-TYPE-5-PHOSPHODIESTERASE-INHIBITORS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="TYPE 5 PHOSPHODIESTERASE INHIBITORS" code="G04BE" /></DRUG1>
<DRUG2>
<CLASS name="STRONG INHIBITORS OF CYP3A4" code="J02-J05" /></DRUG2>
<DESCRIPTION>Increase (very large for the avanafil and the vardenafil) of the plasma concentrations of the type 5 phosphodiesterase inhibitor, with risk of hypotension (severe with the vardenafil)</DESCRIPTION>
<SEVERITY>To know the risks and the levels of constraint for each Type 5 phosphodiesterase inhibitor with the strong inhibitors of CYP3A4, consult the AMM ["Authorisation de la mise au marché", a French document for all medications authorized to be marketed in France with information about them] specific for each one of them.</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>286-TYPE-5-PHOSPHODIESTERASE-INHIBITORS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name=" TYPE 5 PHOSPHODIESTERASE INHIBITORS" code="G04BE" /></DRUG1>
<DRUG2>
<DRUG name="RIOCIGUAT" rxcui="1439816">
<ATC code="C02KX05" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of large drop in blood pressure (synergic effect)</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
</INTERACTIONS>
